Physician profile
Ava Khosraviani
NPI 1578717401
$12,165.16
in general payments reported to CMS, 2019-2025
32 companies · $1,977 in 2025
The $1,977 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,934 · 2020: $678 · 2021: $1,238 · 2022: $1,587 · 2023: $2,508 · 2024: $2,244 · 2025: $1,977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,544 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,544.27 |
| Education | $184.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $1,557.08 | 2019-2025 | Aklief, Epsolay, Oracea |
| Leo Pharma INC. | $1,223.73 | 2019-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $958.03 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $919.04 | 2020-2025 | Winlevi, Ilumya |
| Abbvie INC. | $896.03 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $889.72 | 2019-2025 | |
| Pfizer INC. | $762.71 | 2019-2025 | |
| Allergan, INC. | $655.41 | 2019-2022 | |
| Genzyme Corporation | $532.26 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $527.26 | 2019-2025 | |
| Amgen INC. | $511.33 | 2019-2025 | Otezla, Otezla |
| Ucb, INC. | $336.28 | 2019-2025 | Bimzelx |
| Incyte Corporation | $326.61 | 2022-2025 | Opzelura |
| Journey Medical Corporation | $311.40 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $282.64 | 2019-2025 | Cabtreo, Jublia, Arazlo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $280.18 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $249.30 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Epi Health, LLC | $173.25 | 2019-2022 | |
| Merz North America, INC. | $111.49 | 2023 | Xeomin |
| Glenmark Therapeutics INC. | $83.00 | 2019 | |
| Paratek Pharmaceuticals, INC. | $81.11 | 2024-2025 | Nuzyra |
| Medimetriks Pharmaceuticals, INC. | $71.35 | 2021-2025 | Genadur |
| Dermavant Sciences, INC. | $58.45 | 2023-2024 | Vtama |
| Botanix Sb INC | $53.95 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $52.96 | 2024-2025 | Sotyktu |
| Celgene Corporation | $45.73 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $42.46 | 2019 | |
| Verrica Pharmaceuticals INC. | $42.32 | 2024-2025 | Ycanth |
| Revance Therapeutics, INC. | $38.86 | 2025 | Daxxify |
| Almirall LLC | $38.05 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $26.94 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ava Khosraviani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.